AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21908049 — intervention group
Group type: COMPARATOR
Intervention: Control group (preterm infants)
Number of subjects: 214
Study 21908049 — intervention group
Group type: EXPERIMENTAL
Intervention: Term infants (comparison group)
Number of subjects: 214
Study 19169899 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program (HBIP)
Number of subjects: 185
Study 19169899 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 185
Study 17239678 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with intracoronary injection of BM-SCs
Number of subjects: 360
Study 17239678 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with combined application of BM-SCs
Number of subjects: 360
Study 17239678 — intervention group
Group type: EXPERIMENTAL
Intervention: Late treatment with intracoronary delivery of BM-SCs
Number of subjects: 360
Study 17239678 — intervention group
Group type: EXPERIMENTAL
Intervention: Late treatment with combined administration of BM-SCs
Number of subjects: 360
Study 17239678 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment of AMI (control for all groups)
Number of subjects: 360
Study 15814220 — intervention group
Group type: EXPERIMENTAL
Intervention: RetCam 120
Number of subjects: 15
Study 15814220 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect ophthalmoscope with eyelid speculum
Number of subjects: 15
Study 15814220 — intervention group
Group type: COMPARATOR
Intervention: Indirect ophthalmoscope without eyelid speculum
Number of subjects: 15
Study 12032655 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural beta-carotene (25,000 IU/day)
Number of subjects: 18
Study 12032655 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural vitamin E (400 IU/day)
Number of subjects: 18
Study 12032655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination beta-carotene and vitamin E
Number of subjects: 18
Study 12032655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10580202 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses at 2, 4, and 6 months
Number of subjects: 221
Study 10580202 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose in the Swedish arm
Number of subjects: 221
Study 10580202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth dose in the US arm
Number of subjects: 221
Study 10580202 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diphtheria toxoid dose (25 Lf) in the Swedish arm
Number of subjects: 221
Study 10580202 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tetanus toxoid dose (7 Lf) in the Swedish arm
Number of subjects: 221
Study 10580202 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of doses, prolonging intervals between doses, and increasing antigen amount
Number of subjects: 221
Study 8532944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 50
Study 8532944 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 20 mg once daily
Number of subjects: 50
Study 1840300 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cured composite resin A
Number of subjects: 20
Study 1840300 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cured composite resin B
Number of subjects: 20
Study 6357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.1 mg)
Number of subjects: 6
Study 6357677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29117618 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil omega-3 fatty acids (1,000 mg, twice a day for 12 weeks)
Number of subjects: 60
Study 29117618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27146857 — intervention group
Group type: EXPERIMENTAL
Intervention: Labile group received reminders designed to return memories to a labile state.
Number of subjects: 2
Study 27146857 — intervention group
Group type: COMPARATOR
Intervention: Stable group received reminders designed to leave memories in a stable state.
Number of subjects: 2
Study 27146857 — intervention group
Group type: EXPERIMENTAL
Intervention: Labile group
Number of subjects: 2
Study 25399012 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500mg/d for 3 months)
Number of subjects: 154
Study 25399012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 25399012 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 154
Study 22290281 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 623
Study 22290281 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 623
Study 20099350 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL/second injection rate of gadoxetic acid
Number of subjects: 126
Study 20099350 — intervention group
Group type: COMPARATOR
Intervention: 2 mL/second injection rate of gadoxetic acid
Number of subjects: 126
Study 18294024 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 10 mg/day
Number of subjects: 47
Study 18294024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 50 to 200 mg/day
Number of subjects: 47
Study 17213049 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (CBT) program; specific dosage and duration not mentioned.
Number of subjects: 48
Study 14570627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2 microg kg(‐1x. min(‐1) from the induction of anesthesia to 1 h post‐CPB
Number of subjects: 100
Study 14570627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 1 g/kg added to the CPB prime
Number of subjects: 100
Study 14570627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14570627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol plus dopamine
Number of subjects: 100
Study 14570627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol alone
Number of subjects: 100
Study 10951308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar side‐posture spinal adjusting
Number of subjects: 16
Study 10951308 — intervention group
Group type: EXPERIMENTAL
Intervention: Side‐posture positioning
Number of subjects: 16
Study 10951308 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 16
Study 9007710 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month interferon alpha-2b therapy
Number of subjects: 60
Study 9007710 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month interferon alpha-2b therapy
Number of subjects: 60
Study 1889950 — intervention group
Group type: EXPERIMENTAL
Intervention: Naseptin antiseptic carrier cream
Number of subjects: 48
Study 1889950 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate cautery
Number of subjects: 48
Study 6362203 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose regimen (once-a-day application of fluocinonide combined with three-times-a-day application of its vehicle)
Number of subjects: 52
Study 6362203 — intervention group
Group type: COMPARATOR
Intervention: Traditional dose regimen (four-times-a-day application of fluocinonide)
Number of subjects: 52
Study 31962344 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist (specific doses not mentioned)
Number of subjects: 0
Study 31962344 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist (higher doses)
Number of subjects: 0
Study 31962344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30730430 — intervention group
Group type: EXPERIMENTAL
Intervention: NH‐SiO2
Number of subjects: 40
Study 30730430 — intervention group
Group type: COMPARATOR
Intervention: Homologous bone
Number of subjects: 40
Study 28931586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low added sugars (LAS) diet (5% AS)
Number of subjects: 33
Study 28931586 — intervention group
Group type: EXPERIMENTAL
Intervention: High added sugars (HAS) diet (25% AS)
Number of subjects: 33
Study 28931586 — intervention group
Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 33
Study 27538847 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated home-based exercise program using the Wii game console for 12 weeks
Number of subjects: 30
Study 27538847 — intervention group
Group type: COMPARATOR
Intervention: Conventional home-based physical exercise program for 12 weeks
Number of subjects: 30
Study 25124362 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg
Number of subjects: 20
Study 23070990 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (monthly Web-based conferences and articles on targeting care in RA)
Number of subjects: 50
Study 23070990 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 50
Study 23070990 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study 18562432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (fluoxetine, duloxetine, or Hypericum perforatum)
Number of subjects: 34
Study 18562432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18562432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 34
Study 17550714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarater reliability assessment
Number of subjects: 30
Study 17550714 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability assessment for anterior or posterior angulation
Number of subjects: 30
Study 17550714 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability assessment for varus or valgus angulation
Number of subjects: 30
Study 17550714 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement change assessment
Number of subjects: 30
Study 15368877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anorganic bovine-derived hydroxyapatite matrix (ABM) and cell binding peptide (P-15)
Number of subjects: 10
Study 15368877 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (DEBR)
Number of subjects: 10
Study 11445595 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (3 times/week for 24 weeks, 2 sets of 8-15 repetitions)
Number of subjects: 20
Study 11445595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 9875874 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (5 mg/d for 2 years, then 10 mg/d for the remainder of the trial)
Number of subjects: 4432
Study 9875874 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 4432
Study 9875874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4432
Study 8040954 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endarterectomy (CE) performed within 30 days after stroke (n=42)
Number of subjects: 100
Study 8040954 — intervention group
Group type: COMPARATOR
Intervention: Delayed endarterectomy (CE) performed beyond 30 days after stroke (n=58)
Number of subjects: 100
Study 8040954 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endarterectomy (CE)
Number of subjects: 100
Study 8040954 — intervention group
Group type: COMPARATOR
Intervention: Delayed endarterectomy (CE)
Number of subjects: 100
Study 2647398 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-Choline, 500 mg twice a day orally for 2 to 8 weeks
Number of subjects: 5
Study 2647398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30537305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (60 g protein)
Number of subjects: 11
Study 30537305 — intervention group
Group type: COMPARATOR
Intervention: Low-protein meal (5 g protein)
Number of subjects: 11
Study 28435034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive radical prostatectomy (cRP)
Number of subjects: 46
Study 28435034 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 46
Study 25795462 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term fasting (36 h)
Number of subjects: 9
Study 25795462 — intervention group
Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 9
Study 22797831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist discharge counseling
Number of subjects: 127
Study 22797831 — intervention group
Group type: COMPARATOR
Intervention: Usual patient care
Number of subjects: 127
Study 20102350 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorheopheresis (8 sessions within 10 weeks)
Number of subjects: 16
Study 20102350 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorheopheresis
Number of subjects: 16
Study 20102350 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 eyes)
Number of subjects: 16
Study 19766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 873
Study 19766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Number of subjects: 873
Study 19766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 873
Study 19766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 873
Study 19766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 873
Study 19766459 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 873
Study 17088142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B nasal lavages (25 mL at 100 microg/mL, twice daily for 3 months)
Number of subjects: 116
Study 17088142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 15629023 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photo-coagulation treatment
Number of subjects: 0
Study 15629023 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 11474324 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in the fed state (2 hours after a standardized breakfast)
Number of subjects: 10
Study 11474324 — intervention group
Group type: COMPARATOR
Intervention: Exercise in the fasted state
Number of subjects: 10
Study 11474324 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in the fed state
Number of subjects: 10
Study 10093795 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 0
Study 10093795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8113509 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine/prilocaine cream (EMLA)
Number of subjects: 30
Study 8113509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3291087 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 3291087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29441471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar anodal tDCS
Number of subjects: 14
Study 29441471 — intervention group
Group type: COMPARATOR
Intervention: Bipolar cathodal tDCS
Number of subjects: 14
Study 29441471 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study 28626983 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (SM/FP) with 25/125 mcg per inhalation, 2, 6, and 12 inhalations
Number of subjects: 43
Study 28626983 — intervention group
Group type: COMPARATOR
Intervention: Reference product (SM/FP) with 25/125 mcg per inhalation, 2, 6, and 12 inhalations
Number of subjects: 43
Study 28626983 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (12 inhalations)
Number of subjects: 43
Study 28626983 — intervention group
Group type: COMPARATOR
Intervention: Reference product (12 inhalations)
Number of subjects: 43
Study 28626983 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (2 and 6 inhalations)
Number of subjects: 43
Study 28626983 — intervention group
Group type: COMPARATOR
Intervention: Reference product (2 and 6 inhalations)
Number of subjects: 43
Study 26496366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) with 0.75% ropivacaine and 2% lidocaine with adrenaline
Number of subjects: 60
Study 26496366 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.75% ropivacaine and 2% lidocaine with adrenaline)
Number of subjects: 60
Study 23276413 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic labral repair
Number of subjects: 36
Study 23276413 — intervention group
Group type: COMPARATOR
Intervention: Selective labral debridement
Number of subjects: 36
Study 21638157 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 70
Study 21638157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 18081733 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interferon alpha-2b therapy (1, 2 or 3 MIU TIW depending on response)
Number of subjects: 499
Study 18081733 — intervention group
Group type: COMPARATOR
Intervention: Cyclical interferon alpha-2b therapy (3 MIU TIW for 24 weeks per relapse)
Number of subjects: 499
Study 18081733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (continuous and cyclical therapy)
Number of subjects: 499
Study 16781242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014
Study 16781242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 14636196 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole, 20 mg/kg twice daily for 1 day, with repeat treatment after 10 days
Number of subjects: 23
Study 14636196 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole
Number of subjects: 23
Study 12095157 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Protein C (APC) 12.5 U [2.5 microg]/kg body wt per hour
Number of subjects: 132
Study 12095157 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (8 U/kg body wt per hour)
Number of subjects: 132
Study 9687996 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (ST)
Number of subjects: 220
Study 9687996 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic management (EM)
Number of subjects: 220
Study 7505809 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 micrograms/kg self-administered subcutaneously on days when chemotherapy was not given.
Number of subjects: 40
Study 7505809 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no G-CSF) receiving weekly chemotherapy with cisplatin and etoposide alternating with ifosfamide and doxorubicin.
Number of subjects: 40
Study 7505809 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) arm receiving weekly chemotherapy with G-CSF.
Number of subjects: 40
Study 2679494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg b.i.d. for 8 weeks)
Number of subjects: 10
Study 2679494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 781232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 27
Study 781232 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 27
Study 29757013 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention (sleep hygiene practices and standardized behavioral strategies delivered by trained school nurses)
Number of subjects: 334
Study 29757013 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (Control group)
Number of subjects: 334
Study 28601084 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic oral suspension (POS) for 3 weeks
Number of subjects: 60
Study 25010250 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet patient decision aid (intervention group)
Number of subjects: 122
Study 25010250 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 122
Study 22850326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/100 g alginate
Number of subjects: 121
Study 22850326 — intervention group
Group type: COMPARATOR
Intervention: Control (no added fibre)
Number of subjects: 121
Study 22303756 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty
Number of subjects: 34
Study 22303756 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty
Number of subjects: 34
Study 22303756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 18330493 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 50
Study 18330493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16820123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed frequency (80 Hz and 2 Hz, 3 seconds each)
Number of subjects: 152
Study 16820123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed frequency (20 Hz)
Number of subjects: 152
Study 15662744 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity
Number of subjects: 105
Study 15662744 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 10674588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, vegetarian diet
Number of subjects: 33
Study 9131896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 34
Study 9131896 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 34
Study 9131896 — intervention group
Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 34
Study 9131896 — intervention group
Group type: COMPARATOR
Intervention: L-arginine
Number of subjects: 34
Study 9131896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8442968 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (priming drug) + pancuronium (intubating dose) - Group C
Number of subjects: 90
Study 8442968 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium (priming drug) + d‐tubocurarine (intubating dose) - Group D
Number of subjects: 90
Study 8442968 — intervention group
Group type: COMPARATOR
Intervention: normal saline (control) - Groups A and B
Number of subjects: 90
Study 8442968 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (intubating dose) - Groups B, D, and F
Number of subjects: 90